Fuji Chemical Industry Co. has shifted its commercial cultivation of astaxanthin source Haematococcus pluvialis from its facility in Hawaii to its Swedish facility.
Fuji Chemical Industry Co. has shifted its commercial cultivation of astaxanthin source Haematococcus pluvialis from its facility in Hawaii to its Swedish facility. The company says the decision was made to achieve “better product uniformity, operational efficiency, and ease of expansion.”
Fuji said that although both facilities were fully enclosed bio-systems, each equally producing high levels of astaxanthin, the “two technologies were different [and] consolidating operations into one of the two technologies would avoid duplication of effort and achieve operational efficiency.” It noted that the Swedish facility survived because it can be expanded rapidly.
The company is still considering pursuing algal development at the Hawaii location.
The Nutritional Outlook Podcast Episode 33: Keeping up with contract manufacturing
July 26th 2024Nutritional Outlook talks to Lauren Samot, commercial innovation leader, and Blayney McEneaney, sales executive at Vitaquest International, about trends within the contract manufacturing space, and the ways in which contract manufacturers like Vitaquest keep up with the market and differentiate themselves from the competition.